The state of Illinois currently has 463 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756
Recruiting
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Saint Anthony's Health, Alton, Illinois +54 locations
Conditions: Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Rush - Copley Medical Center, Aurora, Illinois +23 locations
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
NCT05974150
Recruiting
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2023
Locations: Northshore University Health System, Evanston, Illinois
Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Register for Updates
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT03729115
Recruiting
This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.
Gender:
Female
Ages:
25 years and above
Trial Updated:
08/01/2023
Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Illinois Cancer Specialists - Arlington Heights, Arlington Heights, Illinois
Conditions: Breast Cancer
Register for Updates
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894
Recruiting
This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: UroPartners, LLC, Westchester, Illinois
Conditions: Prostate Cancer
Register for Updates
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT04009044
Recruiting
This phase II trial studies how well topical afimoxifene works in treating patients with breast cancer who have undergone radiation therapy on one breast. Topical afimoxifene is a quick-drying medicated gel that may block the growth of breast cancer cells when applied to the breast skin. The purpose of this research is to determine what effect, if any, differences in skin type between women have on the delivery of topical afimoxifene to the breast tissue, and whether radiation affects the delive... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/12/2023
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Register for Updates
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
NCT05943210
Recruiting
This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
07/03/2023
Locations: The University of Chicago, Chicago, Illinois
Conditions: Rectal Cancer
Register for Updates
Empowering Latinas to Obtain Guideline Concordant Screenings
NCT05841355
Recruiting
The design builds on past studies by integrating social network analysis (SNA) and implementation science (IS) into a longitudinal randomized clinical trial (RCT). The investigator will compare the long-term effects of interventions by examining guideline-concordant initial and repeat Brease Cancer (BC) screening.
Gender:
Female
Ages:
Between 50 years and 74 years
Trial Updated:
06/29/2023
Locations: Mile Square Health Center, Chicago, Illinois +1 locations
Conditions: Breast Cancer Screening
Register for Updates
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT04427293
Recruiting
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for 7 and pembrolizumab 200 mg IV on day 1 prior to surgery
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/26/2023
Locations: University of Illinois, Chicago, Illinois
Conditions: Triple Negative Breast Cancer
Register for Updates
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318
Recruiting
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Rush - Copley Medical Center, Aurora, Illinois +43 locations
Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Register for Updates
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT05207709
Recruiting
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Carle Cancer Center, Urbana, Illinois
Conditions: Metastatic Breast Cancer
Register for Updates